2011
Performance of Serum CA125 as a Prognostic Biomarker in Patients With Uterine Papillary Serous Carcinoma
Gupta D, Gunter MJ, Yang K, Lee S, Zuckerwise L, Chen LM, Goldberg GL, Huang GS. Performance of Serum CA125 as a Prognostic Biomarker in Patients With Uterine Papillary Serous Carcinoma. International Journal Of Gynecological Cancer 2011, 21: 529-534. PMID: 21436701, DOI: 10.1097/igc.0b013e31821091b5.Peer-Reviewed Original ResearchConceptsUterine papillary serous carcinomaPapillary serous carcinomaCA125 levelsLymph node metastasisDisease recurrenceCA125 elevationMetastatic diseaseNode metastasisSerum CA125Serous carcinomaStage III/IV diseaseCox proportional hazards regression modelingProportional hazards regression modelingElevated CA125 levelsPreoperative CA125 levelsLymph node involvementRecurrence-free survivalAdvanced International FederationMultivariate survival analysisUPSC patientsMean followSurgical stagingCA125 measurementNode involvementIndependent predictors
2007
Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma
Huang GS, Chiu LG, Gebb JS, Gunter MJ, Sukumvanich P, Goldberg GL, Einstein MH. Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. Gynecologic Oncology 2007, 107: 513-517. PMID: 17935762, PMCID: PMC2696225, DOI: 10.1016/j.ygyno.2007.08.060.Peer-Reviewed Original ResearchConceptsDeep myometrial invasionCA125 elevationExtrauterine diseasePrognostic factorsUterine carcinosarcomaPreoperative CA125CA125 levelsCA125 measurementMyometrial invasionPoor survivalExact testCox proportional hazards modelClinicopathologic prognostic factorsEstrogen receptor positivityIndependent prognostic factorManagement of patientsUnivariate survival analysisUseful serum markerPearson's chi-square testProportional hazards modelFisher's exact testChi-square testSerous histologyConsecutive patientsReceptor positivity